BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

Akcea Therapeutics Inc. (NASDAQ:AKCA) said William Andrews will succeed Louis O’Dea as CMO. Andrews joins the rare disease company from Acer Therapeutics Inc. (NASDAQ:ACER), where he was CMO. Rare disease company Strongbridge Biopharma plc (NASDAQ:SBBP)...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

Lava’s bispecific mAbs targeting γδ T cells could match the potency of other T cell engaging technologies while offering a larger therapeutic window. The company joins a growing group of biotechs focused on γδ T...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BioCentury | Dec 4, 2019
Finance

Series B boost for ImCheck's gamma delta T cell therapies

With $53 million in series B funding, ImCheck plans to bring at least one of its T cell-activating antibodies into the clinic and broaden its immuno-oncology pipeline. Pfizer Ventures and two Bpifrance funds, InnoBio 2...
BioCentury | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM). Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin...
BioCentury | Dec 14, 2018
Finance

Spreading good Kurma

Declaring its last fund’s preseed partnership approach a success, Kurma Partners S.A. is expanding its model to build more new companies across Europe through its new Biofund III. For its 2016 Biofund II, the VC...
BioCentury | Dec 14, 2018
Financial News

Kurma announces first close of €150 million Biofund III

Kurma Partners S.A. completed the first close of its third fund, Kurma Biofund III, which is targeting a final close of €150 million ($169.4 million) in 2019. The firm declined to disclose the size of...
BioCentury | Sep 12, 2018
Company News

Management tracks: Clearside, ImCheck

Clearside Biomedical Inc. (NASDAQ:CLSD) hired Leslie Zacks as general counsel and chief compliance officer. He was VP, general counsel and chief compliance officer at Arbor Pharmaceuticals Inc. (Atlanta, Ga.). Clearside plans to submit an NDA...
BioCentury | Jul 6, 2018
Finance

Dynacure’s quick transfer

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also...
Items per page:
1 - 10 of 18
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

Akcea Therapeutics Inc. (NASDAQ:AKCA) said William Andrews will succeed Louis O’Dea as CMO. Andrews joins the rare disease company from Acer Therapeutics Inc. (NASDAQ:ACER), where he was CMO. Rare disease company Strongbridge Biopharma plc (NASDAQ:SBBP)...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

Lava’s bispecific mAbs targeting γδ T cells could match the potency of other T cell engaging technologies while offering a larger therapeutic window. The company joins a growing group of biotechs focused on γδ T...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BioCentury | Dec 4, 2019
Finance

Series B boost for ImCheck's gamma delta T cell therapies

With $53 million in series B funding, ImCheck plans to bring at least one of its T cell-activating antibodies into the clinic and broaden its immuno-oncology pipeline. Pfizer Ventures and two Bpifrance funds, InnoBio 2...
BioCentury | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM). Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin...
BioCentury | Dec 14, 2018
Finance

Spreading good Kurma

Declaring its last fund’s preseed partnership approach a success, Kurma Partners S.A. is expanding its model to build more new companies across Europe through its new Biofund III. For its 2016 Biofund II, the VC...
BioCentury | Dec 14, 2018
Financial News

Kurma announces first close of €150 million Biofund III

Kurma Partners S.A. completed the first close of its third fund, Kurma Biofund III, which is targeting a final close of €150 million ($169.4 million) in 2019. The firm declined to disclose the size of...
BioCentury | Sep 12, 2018
Company News

Management tracks: Clearside, ImCheck

Clearside Biomedical Inc. (NASDAQ:CLSD) hired Leslie Zacks as general counsel and chief compliance officer. He was VP, general counsel and chief compliance officer at Arbor Pharmaceuticals Inc. (Atlanta, Ga.). Clearside plans to submit an NDA...
BioCentury | Jul 6, 2018
Finance

Dynacure’s quick transfer

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also...
Items per page:
1 - 10 of 18